Sign In
Buy CNS
$80.79
-1.71 (-2.07%)
At Close: Jul 21, 2026
Cohen & Steers and Acadia Realty Trust Acquire Open-Air Shopping Center in Tampa, FL
09:00am, Tuesday, 29'th Oct 2024
NEW YORK , Oct. 29, 2024 /PRNewswire/ -- Cohen & Steers (NYSE: CNS) announced today that funds managed by the Private Real Estate Group of Cohen & Steers and the Investment Management business of Acad
Corero Network Security Introduces Corero Observability & Resiliency Ecosystem (CORE)
07:00am, Tuesday, 29'th Oct 2024
New Platform Provides Real-Time Traffic Analytics, Threat Intelligence, Application Layer Protection, and Anti-Bot DDoS Defense To Enhance Service Availability and Security MARLBOROUGH, Mass. , Oct.
Corero Network Security Launches New Scalable 400G DDoS Hardware Appliance with Exclusive Trade-In Program
07:00am, Thursday, 24'th Oct 2024
Customers Seeking Appliance Upgrades Can Trade in Existing Hardware MARLBOROUGH, Mass. , Oct. 24, 2024 /PRNewswire/ -- Corero Network Security (AIM: CNS) (OTCQB: DDOSF), the distributed denial of ser
CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
02:50pm, Wednesday, 23'rd Oct 2024
HOUSTON, TX / ACCESSWIRE / October 23, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for prim
Cohen & Steers Stock : A Buy With Results Beat And Positive Outlook
08:29am, Monday, 21'st Oct 2024
Cohen & Steers' Q3 2024 results exceeded expectations, with revenue up 9.4% YoY and non-GAAP adjusted EPS up 13.5% YoY. Significant AUM growth and a return to positive net inflows drove the strong fin
Cohen & Steers, Inc. (CNS) Q3 2024 Earnings Call Transcript
02:09pm, Thursday, 17'th Oct 2024
Cohen & Steers, Inc. (NYSE:CNS ) Q3 2024 Earnings Conference Call October 17, 2024 10:00 AM ET Company Participants Brian Heller - Senior Vice President and Corporate Counsel Jon Cheigh - Chief Invest
COHEN & STEERS REPORTS RESULTS FOR THIRD QUARTER 2024
04:19pm, Wednesday, 16'th Oct 2024
NEW YORK , Oct. 16, 2024 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported its results for the quarter ended September 30, 2024. The earnings release along with the accompanying earnings
CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment
09:00am, Thursday, 10'th Oct 2024
Segment featuring members of the CNS management team and leading Neuro-Oncologist and Key Opinion Leader, Dr. Samuel Goldlust Access the segment here HOUSTON, TX / ACCESSWIRE / October 10, 2024 / CNS
Neurocrine: A Buy Amid CNS Pipeline Growth And Ingrezza's Strength (Rating Upgrade)
07:42am, Thursday, 10'th Oct 2024
Neurocrine Biosciences' Ingrezza has grown into a multibillion-dollar drug, but the company's stock has underperformed the S&P 500 since 2019. Neurocrine's NBI-1117568 demonstrated encouraging Phase 2
Cohen & Steers, Inc. to Release Third Quarter 2024 Results on October 16, 2024
04:41pm, Wednesday, 09'th Oct 2024
NEW YORK , Oct. 9, 2024 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced that it expects to release third quarter 2024 results after the market closes on Wednesday, October 16, 2024. The ear
Cohen & Steers Announces Preliminary Assets Under Management and Net Flows For September 2024
04:23pm, Tuesday, 08'th Oct 2024
NEW YORK , Oct. 8, 2024 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $91.8 billion as of September 30, 2024, an increase of $3.7 billion from
CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC
09:15am, Tuesday, 08'th Oct 2024
Live webcast fireside chat on Wednesday, October 16th at 4:00 PM ET HOUSTON, TX / ACCESSWIRE / October 8, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical c
Study shows the repeated long-term, as-needed use of STS101 for the acute treatment of a migraine attack demonstrated a favorable safety profile and was well tolerated. Exploratory Efficacy Endpoints
Corero Network Security Secures $6M in New Orders To Close Q3 2024
07:00am, Tuesday, 08'th Oct 2024
Total Orders for 2024 Reach $20.2 Million LONDON , Oct. 8, 2024 /PRNewswire/ -- Corero Network Security (AIM: CNS) (OTCQB: DDOSF), the distributed denial of service (DDoS) protection specialists, to
NeOnc Technologies Receives Pharma Tech Outlook's Top Drug Delivery Platform Award for 2024
11:00am, Monday, 07'th Oct 2024
NeOnc's Novel Intranasal Approach to Bypassing the Blood Brain Barrier with Therapeutics for CNS Diseases Featured as Cover Page Story in Recent Edition of Pharma Tech Outlook NeOnc's Novel Intranasal
